A study of Harvoni (ledipasvir/sofosbuvir) for the treatment of genotype 1 or 2 HCV-infecteion in patients with active HBV co-infection

Trial Profile

A study of Harvoni (ledipasvir/sofosbuvir) for the treatment of genotype 1 or 2 HCV-infecteion in patients with active HBV co-infection

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Apr 2017 New trial record
    • 21 Apr 2017 According to a Gilead media release, the company presented results from this study at the International Liver Congress 2017.
    • 21 Apr 2017 Results published in the Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top